 |
Then the team began to analyze the various technologies that are available for
the measurement of multiple proteins in the blood and developed a model that
describes their weaknesses and limitations. They discovered why so far, was the
number of proteins, which can simultaneously measure limited and therefore the
accuracy of these kinds of tests were to maintain so difficult. Once they had a
better understanding of this process, they were able to build your arsenal of
micro to work around these limitations. The new technology enables measurement
of protein biomarkers, and the doctor wants to try to minimize the number of
false alarms.
The research team has teams Bioinformatics oncology and could measure the profile of 32 different proteins in the blood of 11 healthy volunteers and 17 women with an individual. They discovered that a subset of six of the 32 proteins could be used to provide a fingerprint for this type of cancer can be determined and used to classify each different patient and / or healthy controls, either with or n ' without breast cancer.
The researcher’s hope that this work may lead to development of a diagnostic test can be easily performed in a physician's office by a single drop of blood. They hope that this technology will be able to reduce the dependence on mammography and women's exposure to harmful X-rays at the same time minimizing costs. Researchers are trying to a portable device that will be able to develop this test is. Breast Cancer preserve For now recognize a single skein of blood:
Nearly one in eight women will be diagnosed with breast cancer eventually in their lives. Everyone knows that early detection is the key to long-term survival. Early detection remains a challenge because of the problems associated with mammography: the high price and the lack of portability as a diagnostic tool. Sometimes breast cancer can be detected in a mammogram, once it has reached an advanced stage. That could soon change because of a new matrix developed by biomedical engineers at McGill University in Montreal, Quebec. They published their findings recently in the publication of Molecular and Cellular Proteomics »April.
Scientists are struggling to develop a blood test for cancer based on the presence of something called CEA antigen Carcinoembyronic or is a biomarker for cancer, 40 years ago by Dr. Phil Gold was discovered, McGill University. The problem is that this biomarker is detectable in healthy individuals, and the detected amount can vary from one individual to another in different genetic backgrounds and lifestyle of the individual. For this reason, the scientists were able to determine the exact relationship between cutting healthy people and people who have cancer.
McGill team began to try to overcome this problem by measuring the concentration of various proteins in the blood and signature identification of molecules that, when analyzed together, a specific "fingerprints cancer." This day, not isolate able this type of cancer fingerprints.
The research team has teams Bioinformatics oncology and could measure the profile of 32 different proteins in the blood of 11 healthy volunteers and 17 women with an individual. They discovered that a subset of six of the 32 proteins could be used to provide a fingerprint for this type of cancer can be determined and used to classify each different patient and / or healthy controls, either with or n ' without breast cancer.
The researcher’s hope that this work may lead to development of a diagnostic test can be easily performed in a physician's office by a single drop of blood. They hope that this technology will be able to reduce the dependence on mammography and women's exposure to harmful X-rays at the same time minimizing costs. Researchers are trying to a portable device that will be able to develop this test is. Breast Cancer preserve For now recognize a single skein of blood:
Nearly one in eight women will be diagnosed with breast cancer eventually in their lives. Everyone knows that early detection is the key to long-term survival. Early detection remains a challenge because of the problems associated with mammography: the high price and the lack of portability as a diagnostic tool. Sometimes breast cancer can be detected in a mammogram, once it has reached an advanced stage. That could soon change because of a new matrix developed by biomedical engineers at McGill University in Montreal, Quebec. They published their findings recently in the publication of Molecular and Cellular Proteomics »April.
Scientists are struggling to develop a blood test for cancer based on the presence of something called CEA antigen Carcinoembyronic or is a biomarker for cancer, 40 years ago by Dr. Phil Gold was discovered, McGill University. The problem is that this biomarker is detectable in healthy individuals, and the detected amount can vary from one individual to another in different genetic backgrounds and lifestyle of the individual. For this reason, the scientists were able to determine the exact relationship between cutting healthy people and people who have cancer.
McGill team began to try to overcome this problem by measuring the concentration of various proteins in the blood and signature identification of molecules that, when analyzed together, a specific "fingerprints cancer." This day, not isolate able this type of cancer fingerprints.
No comments:
Post a Comment